Objectives Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …

Lung transplantation offers a survival benefit in well chosen patients with end-stage lung
diseases. However, CLAD, side effects of immunosuppressive therapy and solid organ …

Tens of thousands of patients with advanced lung diseases may be eligible to be considered
as potential candidates for lung transplant around the world each year. The timing of referral …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis.
Lung transplantation is the only intervention shown to increase life expectancy for patients …

Patients with chronic lung diseases, particularly interstitial lung disease and chronic
obstructive pulmonary disease, frequently develop pulmonary hypertension, which results in …

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Recent studies have
identified the key role of crosstalk between dysregulated epithelial cells, mesenchymal …

Lung transplantation (LTx) can be a life-extending treatment option for patients with
advanced and/or progressive fibrotic interstitial lung disease (ILD), especially idiopathic …

The immune system is receiving increasing attention for interstitial lung diseases, as
knowledge on its role in fibrosis development and response to therapies is expanding …

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown origin
that usually results in death from secondary respiratory failure within 2–5 years of diagnosis …

Idiopathic pulmonary fibrosis (IPF) is a progressive, degenerative pulmonary condition.
Transforming growth factor (TGF)-β, platelet-derived growth factor (PDGF), and tumor …